NUCALA REDUCED NASAL POLYP SURGERY

PROVEN PROTECTION AGAINST SURGERY1

57% reduction in the proportion of patients who had survery vs placebo infographic 57% reduction in the proportion of patients who had survery vs placebo infographic

Key secondary endpoint: Time to next surgery up to Week 52; NUCALA + SOC (n=18/206) vs placebo + SOC (n=46/201), HR: 0.43; P=0.0032.

SUBGROUP OF PATIENTS WITH 1 PRIOR NASAL POLYP SURGERY2

73% reduction in proportion of patients who had surgery vs placebo in a subgroup of patients with 1 prior nasal polyp surgery infographic 73% reduction in proportion of patients who had surgery vs placebo in a subgroup of patients with 1 prior nasal polyp surgery infographic

Time to next surgery up to Week 52 for 1 prior surgery:
NUCALA (n=6/108) vs placebo (16/81); HR: 0.27 (95% CI: 0.10, 0.69).

Time to next surgery up to Week 52 for 1 prior surgery: NUCALA (n=6/108) vs placebo (16/81); HR: 0.27 (95% CI: 0.10, 0.69).

  • 2 prior surgeries, NUCALA (n=5/47) vs placebo (n=9/47); HR: 0.79 (95% CI: 0.24, 2.61).
  • >2 prior surgeries, NUCALA (n=7/51) vs placebo (n=21/73); HR: 0.48 (95% CI: 0.20, 1.16).

Post hoc analysis. All results are descriptive.

SYNAPSE study design

Request a rep

Want to know more?

Request a rep

Reduction in nasal polyp surgery since last surgery3

72% reduction in proportion of patients who had surgery up to Week 52 vs placebo in a subgroup of patients with surgery in past 3 years infographic 72% reduction in proportion of patients who had surgery up to Week 52 vs placebo in a subgroup of patients with surgery in past 3 years infographic

NUCALA (n=80) vs placebo (n=100); HR: 0.28 (95% CI: 0.09, 0.84).

50% reduction in proportion of patients who had surgery up to Week 52 vs placebo in a subgroup of patients with 3+ years since last surgery infographic 50% reduction in proportion of patients who had surgery up to Week 52 vs placebo in a subgroup of patients with 3+ years since last surgery infographic

NUCALA (n=125) vs placebo (n=100); HR: 0.50 (95% CI: 0.26, 0.98).

Post hoc analysis. All results are descriptive.

SYNAPSE study design

CI=confidence interval; HR=hazard ratio; SOC=standard of care.

Two OCS pills

Learn how NUCALA reduced steroid use for nasal polyps

SEE STEROID DATA

NUCALA Prescription

Navigate a NUCALA prescription

Get patients started